A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation
- Registration Number
- NCT01989234
- Lead Sponsor
- SK Life Science, Inc.
- Brief Summary
This will be a multi-center, randomized, double-blind, placebo-controlled study of YKP10811 capsules in patients with chronic idiopathic constipation. Following a 2-week baseline period, approximately 320 eligible patients with \<3 complete spontaneous bowel movements (CSBM) and ≤ 5 SBMs per week will be randomly assigned equally to receive one of the following oral treatments; placebo or YKP10811 capsules once daily for 12 weeks followed by a 2 week follow-up period.
The objectives of this study are:
* To assess the efficacy of YKP10811 once daily at relieving constipation and associated symptoms in subjects with chronic idiopathic constipation.
* To determine the safety and tolerability of YKP10811 once daily in subjects with chronic idiopathic constipation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 334
- Patients who meet modified Rome II criteria for Chronic Constipation.
- Patients who are male or female, 18 to 65 years of age inclusive.
- At Visit 3, patients must have < 3 CSBMs per week and ≤ 5 SBMs per week during the 2-week baseline period.
- Patients who meet Rome II criteria for Irritable Bowel Syndrome (IBS-C).
- Patients with constipation that is drug-induced, or secondary to endocrine, metabolic or, surgery.
- Patients with a clinically significant diseases that would limit the patient's ability to complete and/or participate in the study, including gastrointestinal disorder or surgery, an endocrine abnormality (e.g., diabetes), impaired renal function (GFR of < 55mL/minute/1.73m2), uncontrolled pulmonary diseases (including asthma), uncontrolled cardiovascular disease (a history of myocardial infarction or cerebrovascular accident within 6 months prior to screening) or significant neurological diseases.
- Patients with a history of inflammatory bowel disease.
- Patients with a history of cancer (other than basal cell or squamous cell carcinoma of the skin completely excised) unless the malignancy has been in complete remission for at least 5 years prior to screening.
- Patients who started a special diet and/or an intense physical workout program within 30 days prior to the beginning of the baseline period or who are intending to substantially modify their dietary habits at any time during the study (patients on a stable, continuous regimen of fiber therapy for at least 30 days prior to the pretreatment baseline period are allowed to continue that therapy, provided that they continue at a constant dose throughout the study.
- Patients with a history of clinically significant hypersensitivity or allergy (facial swelling, hives, breathing difficulty, Stevens-Johnson syndrome etc), in response to any medication, either prescription or nonprescription including an investigational drug, dietary supplement, or herbal medicine.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description YKP10811 High Dose YKP10811 YKP10811 High Dose YKP10811 Mid Dose YKP10811 YKP10811 Mid Dose YKP10811 Low Dose YKP10811 YKP10811 Low Dose Placebo Comparator Placebo Placebo Comparator
- Primary Outcome Measures
Name Time Method The proportion of subjects with improved bowel movement frequency 12 weeks
- Secondary Outcome Measures
Name Time Method Onset time to CSBM 12 weeks Daily average ratings of stool consistency 12 weeks Instances of rescue medicine usage 12 weeks Abdominal discomfort 12 weeks Constipation severity 12 weeks Severity of straining 12 weeks Bloating 12 weeks Onset time to SBM 12 weeks Abdominal pain 12 weeks Stool frequency 12 weeks
Trial Locations
- Locations (65)
Alliance Clinical Research
🇺🇸Oceanside, California, United States
Clinical Research Advantage, Inc. / Warner Family Practice, PC
🇺🇸Chandler, Arizona, United States
Connect Clinical Research Center
🇺🇸Chandler, Arizona, United States
Clinical Research Advantage, Inc. / Central Phoenix Medical Clinic, LLC
🇺🇸Phoenix, Arizona, United States
Arizona Research Center
🇺🇸Phoenix, Arizona, United States
Applied Research Center Arkansas, Inc.
🇺🇸Little Rock, Arkansas, United States
Digestive & Liver Disease Specialists, A Medical Group, Inc.
🇺🇸Anaheim, California, United States
Precision Research Institute
🇺🇸Chula Vista, California, United States
Triwest Research Associates, LLC
🇺🇸El Cajon, California, United States
Diagnamics Inc.
🇺🇸Encinitas, California, United States
Scroll for more (55 remaining)Alliance Clinical Research🇺🇸Oceanside, California, United States